Kineta Beheer

Name: Financiële inzichten gebaseerd op S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

CEO

Kineta heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Craig Philips	President & Secretary	2yrs	US$993.40k	0.78% $ 72.5k
Keith Baker	Chief Financial Officer	2yrs	US$813.69k	0.14% $ 12.8k
Thierry Guillaudeux	Chief Scientific Officer	2yrs	geen gegevens	0.18% $ 16.5k
Gary Gentges	Executive Vice President of Corporate Development	no data	geen gegevens	geen gegevens
Pauline Kenny	Advisor	less than a year	US$741.73k	0.15% $ 14.0k

2.0yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KANT wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Arkowitz	Independent Director	2yrs	US$141.55k	0.023% $ 2.1k
Kimberlee Drapkin	Independent Director	1.5yrs	US$69.85k	0% $ 0
Shawn P. Iadonato	Chairman of the Board	2yrs	US$1.28m	5.61% $ 522.9k
Raymond Bartoszek	Independent Director	2yrs	US$86.37k	14.68% $ 1.4m
Marion Foote	Independent Director	2yrs	US$90.12k	1.17% $ 108.8k
Scott Dylla	Independent Director	1.5yrs	US$66.10k	0.033% $ 3.0k
Richard Peters	Lead Independent Director	2yrs	US$148.18k	0.73% $ 68.4k
Lisa Coussens	Member of Scientific Advisory Board	4.7yrs	geen gegevens	geen gegevens
Patricia LoRusso	Member of Scientific Advisory Board	4.7yrs	geen gegevens	geen gegevens
Michael Curran	Member of Scientific Advisory Board	4.7yrs	geen gegevens	geen gegevens
Evan Yu	Member of Scientific Advisory Board	1.8yrs	geen gegevens	geen gegevens
Myriam Chalabi	Member of Scientific Advisory Board	1.8yrs	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KANT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

Kineta Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Board Appointments

No independent directors

Recent updates

TuHURA Biosciences, Inc. (NasdaqCM:HURA) entered into a definitive agreement to acquire Kineta, Inc.

Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer (2024)

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123

Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index

Nasdaq Suspends Trading of Kineta's Common Stock Following Denial of Continued Listing Request, Effective September 19, 2024 and to File Form 25-NSE with the Securities and Exchange Commission

Kineta, Inc.(OTCPK:KANT) dropped from NASDAQ Composite Index

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Kineta, Inc. Re Opens Enrollment for the Vista-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Kineta Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta Receives Written Notice from Nasdaq Regarding Non-Compliance Minimum Closing Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial

Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Restructuring and Workforce Reduction

Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity

Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors

Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial

New major risk - Share price stability

Kineta Regains Compliance with Nasdaq Listing Rules

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kineta, Inc. Announces Board Appointments

Third quarter 2022 earnings released

No independent directors

Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. (NasdaqCM:YMTX) from a group of shareholders in a reverse merger transaction.

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd